Light during darkness and cancer: Relationships in circadian photoreception and tumor biology

Cancer Causes and Control

Volumn 17, Issue 4, 2006, Pages 515-523

  Jasser, Samar A ^a   Blask, David E ^b   Brainard, George C ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BASSETT RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Circadian rhythm; Light; Melatonin; Photoreception

Indexed keywords

MELANOPSIN; MELATONIN; PIGMENT;

BIOLOGY; BREAST CANCER; CANCER; CANCER RISK; CIRCADIAN RHYTHM; DARKNESS; EMPIRICISM; EXPOSURE; HUMAN; HYPOTHALAMUS; LIFESTYLE; LIGHT; NIGHT; NONHUMAN; ONCOLOGY; PHOTOSENSITIVITY; PHOTOTRANSDUCTION; PHYSIOLOGY; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA GANGLION CELL; REVIEW; RISK ASSESSMENT; RODENT; SUPRACHIASMATIC NUCLEUS; VISUAL SYSTEM;

ANIMALS; CIRCADIAN RHYTHM; DARKNESS; HUMANS; LIGHT; MELATONIN; NEOPLASMS; PHOTOTRANSDUCTION; SUPRACHIASMATIC NUCLEUS;

EID: 33645530701     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-005-9013-6     Document Type: Review

References (96)

1. Hastings MH, Reddy AB, Maywood ES (2003) A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 4:649-661
2. Refinetti R (2000) Circadian Physiology. CRC Press, Boca Raton, Florida, 1-184
3. Stevens RG, Wilson BW, Anderson LE (eds) (1997) The Melatonin Hypothesis: Breast Cancer and Use of Electric Power. Columbus, Battelle Press, Ohio, pp 1-760
4. Brainard GC, Rollag MD, Hanifin JP (1997) Photic regulation of melatonin in humans: ocular and neural signal transduction. J Biol Rhythms 12:537-546
5. Brainard GC, Hanifin JP (2005) Photons, clocks and consciousness. J Biol Rhythms 20:314-325
6. Reiter RJ, (1991) Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 12:151-180
7. Brzezinski A, (1997) Melatonin in humans. N Engl J Med 336:186-195
8. Lewy AJ, Sack RL, Miller LS, Hoban TM (1987) Antidepressant and circadian phase-shifting effects of light. Science 235:352-354
9. Lewy AJ, Bauer VK, Cutler NL, et al. (1998) Morning vs evening light treatment of patients with winter depression. Arch Gen Psychiatry 55:890-896
10. Terman JS, Terman M, Lo ES, Cooper TB (2001) Circadian time of morning light administration and therapeutic response in winter depression. Arch Gen Psychiatry 58:69-75
11. Lam RW (ed.) (1998) Seasonal Affective Disorder and Beyond: Light Treatment for SAD and Non-SAD Disorders. American Psychiatric Press, Washington, D.C., pp 1-327
12. Terman M, Terman JS, Ross DC (1998) A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Arch Gen Psychiatry 55:875-882
13. Eastman CI, Young MA, Fogg LF, Liu L, Meaden PM (1998) Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry 55:883-889
14. Tamarkin L, Danforth D, Lichter A, et al. (1982) Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 216:1003-1005
15. Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellman O, Gupta D (1989) Stage-dependent depression of melatonin in patients with primary breast cancer. Cancer 64:426-433
16. Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler KH, Fluchter SH (1992) Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine or primary prostrate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta 209:153-167
17. Blask DE (1984) The pineal: an oncostatic gland? In: Reiter RJ (ed.) The Pineal Gland. Raven Press, New York, 253-284
18. Blask DE, Sauer LA, Dauchy RT, Holowachuk EW, Ruhoff MS, Kopff HE (1999) Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 59:4693-4701
19. Reiter RJ (1994) Melatonin: multifaceted messenger to the masses. Lab Med 25:438-443
20. Cos S, Blask DE (1994) Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J Pineal Res 17:25-32
21. Blask DE, Sauer LA, Dauchy RT (2002) Melatonin as a chronobiotic/ anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2:113-132
22. Panzer A, Viljoen M (1997) The validity of melatonin as an oncostatic agent. J Pineal Res 22:184-202
23. Stevens RG, Rea MS (2001) Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control 12:279-287
24. Stevens RG (2001) Circadian disruption and breast cancer. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D (eds) The Pineal Gland and Cancer: Neuroendocrine Mechanisms in Malignancy. Springer-Verlag, Berlin, 511-517
25. Lissoni P, Barni S, Meregalli S, et al. (1995) Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 71:854-856
26. Lissoni P, Meregalli S, Nosetto L, et al. (1996) Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 53:43-46
27. Gonzalez R, Sanchez A, Ferguson JA, et al. (1991) Melatonin therapy of advanced human malignant melanoma. Melanoma Res 1:237-243
28. Hill SM, Spriggs LL, Simon MA, Muraoka H, Blask DE (1992) The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett 64:249-256
29. Crespo D, Fernandez-Viadero C, Verduga R, Ovejero V, Cos S (1994) Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. J Pineal Res 16:215-222
30. Nathan PJ, Norman TR, Burrows GD (1999) Effect of menstrual cycle stage on the melatonin suppression by dim white light. Psychoneuroendocrinology 24:193-200
31. Filipski E, Delaunay F, King VM, et al. (2004) Effects of chronic jet lag on tumor progression in mice. Cancer Res 64:7879-7885
32. Lewy AJ, Sack RA, Singer CL (1984) Assessment and treatment of chronobiologic disorders using plasma melatonin levels and bright light exposure: the clock-gate model and the phase response curve. Psychopharmacol Bull 20:561-565
33. Klein DC, Moore RY, Reppert SM (eds) (1991) Suprachiasmatic Nucleus: The Mind's Clock. Oxford University Press, Oxford, pp 5-456
34. Berson DM, Dunn FA, Takao M (2002) Phototransduction by retinal ganglion cells that set the circadian clock. Science 295:1070-1073
35. Berson DM (2003) Strange vision: ganglion cells as circadian photoreceptors. Trends Neurosci 26:314-320
36. Provencio I, Rollag MD, Castrucci AM (2002) Photoreceptive net in the mammalian retina. Nature 415:493
37. Gooley JJ, Lu J, Fischer D, Saper CB (2003) A broad role for melanopsin innonvisual photoreception. J Neurosci 23:7093-7106
38. Provencio I, Rodriguez IR, Jiang G, Hayes WP, Moreira EF, Rollag MD (2000) A novel human opsin in the inner retina. J Neurosci 20:600-605
39. Hannibal J, Hindersson P, Ostergaard J, et al. (2004) Melanopsin is expressed in PACAP-containing retinal ganglion cells of the human retinohypothalamic tract. Invest Ophthalmol Vis Sci 45:4202-4209
40. Kumbalasiri T, Provencio I (2005) Melanopsin and other novel mammalian opsins. Exp Eye Res 81:368-375
41. Partch CL, Sancar A (2005) Cryptochromes and circadian photoreception in animals. Methods Enzymol 393:726-745
42. Van Gelder RN (2005) Nonvisual ocular photoreception in the mammal. Methods Enzymol 393:746-755
43. Melyan Z, Tarttelin EE, Bellingham J, Lucas RJ, Hankins MW (2005) Addition of human melanopsin renders mammalian cells photoresponsive. Nature 433:741-745
44. Qiu X, Kumbalasiri T, Carlson SM, et al. (2005) Induction of photosensitivity by heterologous expression of melanopsin. Nature 433:745-749
45. Panda S, Nayak SK, Campo B, Walker JR, Hogenesch JB, Jegla T (2005) Illumination of melanopsins signaling pathway. Science 307:600-604
46. Dacey DM, Liao H-W, Peterson BB, et al. (2005) Melanopsin-expressing ganglion cells in primate retina signal colour and irradiance and project to the LGN. Nature 433:749-754
47. Pevet P, Heth G, Hiam A, Nevo E (1984) Photoperiod perception in the blind mole rat (Spalax ehrenbergi, Nehring): involvement of the Harderian gland, atrophied eyes, and melatonin. J Exp Zool 232:41-50
48. Webb SM, Champney TH, Lewinski AK, Reiter RJ (1985) Photoreceptor damage and eye pigmentation: influence on the sensitivity of rat pineal N-acetyltransferase activity and melatonin levels to light at night. Neuroendocrinology 40:205-209
49. Foster RG, Provencio I, Hudson D, Fiske S, DeGrip W, Menaker M (1991) Circadian photoreception in the retinally degenerate mouse (rd/rd). J Comp Physiol [A] 169:39-50
50. Arendt J (1998) Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. Rev Reprod 3:13-22
51. Brainard GC, Hanifin JP, Greeson JM, et al. (2001) Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci 21:6405-6412
52. Thapan K, Arendt J, Skene DJ (2001) An action spectrum for melatonin suppression: evidence for a novel non-rod, non-cone photoreceptor system in humans. J Physiol 535:261-267
53. Brainard GC, Hanifin JP, Rollag MD, et al. (2001) Human melatonin regulation is not mediated by the three cone photopic visual system. J Clin Endocrinol Metab 86:433-436
54. Lockley SW, Brainard GC, Czeisler CA (2003) High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light. J Clin Endocrinol Metab 88:4502-4505
55. Yoshimura T, Ebihara S (1996) Spectral sensitivity of photoreceptors mediating phase-shifts of circadian rhythms in retinally degenerate CBA/J (rd/rd) and normal CBA/N (+/+) mice. J Comp Physiol [A] 178:797-802
56. Ruby N, Brennan T, Xie X, et al. (2002) Role of melanopsin in circadian responses to light. Science 298:2211-2213
57. Panda S, Sato TK, Castrucci AM, et al. (2002) Melanopsin (Opn4) requirement for normal light-induced circadian phase-shifting. Science 298:2213-2216
58. Hankins MW, Lucas RJ (2002) The primary visual pathway in humans is regulated according to long-term light exposure through the action of a nonclassical photopigment. Curr Biol 12:191-198
59. Morin LP, Blanchard JH, Provencio I (2003) Retinal ganglion cell projections to the hamster suprachiasmatic nucleus, intergeniculate leaflet, and visual midbrain: bifurcation and melanopsin immunoreactivity. J Comp Neurol 465:401-416
60. Czeisler CA, Shanahan TL, Klerman EB, et al. (1995) Suppression of melatonin secretion in some blind patients by exposure to bright light. N Engl J Med 332:6-11
61. Klerman EB, Shanahan TL, Brotman DJ, et al. (2002) Photic resetting of the human circadian pacemaker in the absence of conscious vision. J Biol Rhythms 17:548-555
62. Ruberg FL, Skene DJ, Hanifin JP, et al. (1996) Melatonin regulation in humans with color vision deficiencies. J Clin Endocrinol Metab 81:2980-2985
63. Hahn RA (1991) Profound bilateral blindness and the incidence of breast cancer. Epidemiology 2:208-210
64. Feychting M, Osterlund B, Ahlbom A (1998) Reduced cancer incidence among the blind Epidemiology 9:490-494
65. Zacharias L, Wurtman RJ (1964) Blindness: its relation to the age of menarche. Science 144:1154-1155
66. Brainard GC, Lewy AJ, Menaker M, et al. (1988) Dose-response relationship between light irradiance and the suppression of melatonin in human volunteers. Brain Res 454:212-218
67. Glickman G, Levin R, Brainard GC (2002) Ocular input for human melatonin regulation: relevance to breast cancer. Neuroendocrinol Lett 23:17-22
68. Zeitzer JM, Dijk D-J, Kronauer RE, Brown EN, Czeisler CA (2000) Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J Physiol 526:695-702
69. Dauchy RT, Sauer LA, Blask DE, Vaughan GM (1997) Light contamination during the dark phase in "photoperiodically controlled" animal rooms: effect on tumor growth and metabolism in rats. Lab Anim Sci 47:511-518
70. Dauchy RT, Blask DE, Sauer LA, Brainard GC, Krause JA (1999) Dim light during darkness stimulates tumor progression by enhancing tumor fatty acid uptake and metabolism. Cancer Lett 144:131-136
71. Aggelopoulos NC, Meissl H (2000) Responses of neurones of the rat suprachiasmatic nucleus to retinal illumination under photopic and scotopic conditions. J Physiol 523:211-222
72. Smith KA, Schoen MW, Czeisler CA (2004) Adaptation of human pineal melatonin suppression by recent photic history. J Clin Endocrinol Metab 89:3610-3614
73. Hebert M, Martin SK, Lee C, Eastman CI (2002) The effects of prior light history on the suppression of melatonin by light in humans. J Pineal Res 33:198-203
74. Brainard GC, Hanifin JP (2004) The effects of light on human health and behavior: relevance to architectural lighting. Vienna: CIE x027:2-16
75. Cajochen C, Munch M, Kobialka S, et al. (2005) High sensitivity of human melatonin, alertness, thermoregulation and heart rate to short wavelength light. J Clin Endocrinol Metab 90:1311-1316
76. Lipson ED (1994) Action spectroscopy: methodology. In: Horspool WM, Song P-S (eds) Organic Photochemistry and Photobiology. CRC Press, New York, 1257-1266
77. Matthes R, Sliney D, Didomenico S, Murray P, Phillips R, Wengraitis S (eds) (1999) Measurements of Optical Radiation Hazards. ICNIRP, Munchen, Germany, pp 1-762
78. Hrushesky WJM (2001) Melatonin cancer therapy. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D (eds) The Pineal Gland and Cancer: Neuroendocrine Mechanisms in Malignancy. Springer-Verlag, Berlin, 476-508
79. Davis S, Mirick DK, Stevens RG (2001) Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557-1562
80. Schernhammer ES, Laden F, Speizer FE, et al. (2001) Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 93:1563-1568
81. Parkin DM, Laara E, Muir CS (1988) Estimates of worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41:184-197
82. Stevens RG (1987) Electric power use and breast cancer: a hypothesis. Am J Epidemiol 125:556-561
83. Stevens RG, Davis S (1996) The melatonin hypothesis: electric power and breast cancer. Environ Health Perspect 104:135-140
84. Blask DE, Dauchy RT, Sauer LA, Krause JA, Brainard GC (2003) Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression. Breast Cancer Res Treat 79:313-320
85. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP (1980) Light suppresses melatonin secretion in humans. Science 210:1267-1269
86. Blask DE, Brainard GC, McGowan T, Kesselring J (2004) Relationship Between Light and the Development and Growth of Internal Solid Cancers: A Review of Current Research and the Potential Implications for Lighting Practice. EPRI, Palo Alto, CA, and McClung Foundation, Conyers, GA, 1011162
87. Blask DE, Dauchy RT, Sauer LA, Krause JA, Brainard GC (2002) Light during darkness, melatonin suppression and cancer progression. Neuroendocrinol Lett 23:52-56
88. Dauchy RT, Blask DE, Brainard GC, et al. (2003) Low-intensity light exposure during animal room dark phase and alterations in tumor growth rate and metablolism in rats: a dose-response relationship. Contemp TopLab Anim Sci 42:101
89. Nanda K, Bastian LA, Schulz K (2002) Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 186:325-334
90. Falkenberry SS, Legare RD (2002) Risk factors for breast cancer. Obstet Gynecol Clin North Am 29:159-172
91. MacMahon B, Cole P, Brown J (1973) Etiology of human breast cancer: a review. J Natl Cancer Inst 50:21-42
92. Kushi L, Giovannucci E (2002) Dietary fat and cancer. Amer J Med 113:63S-70S
93. Bianchini F, Kaaks R, Vainio H (2002) Overweight, obesity, and cancer risk. Lancet Oncol 3:565-574
94. Giovannucci E (2002) Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 31:925-943
95. Ressel GW (2002) Amercan Cancer Society releases guidelines on nutrition and physical activity for cancer prevention. Am Fam Physician 66:1555, 1559-1560, 1562
96. White JD (2002) Cancer: current research in alternative therapies. Prim Care 29:379-392